Last reviewed · How we verify

Intraoperative infusion of dexmedetomidine

Nanjing First Hospital, Nanjing Medical University · FDA-approved active Small molecule

Intraoperative infusion of dexmedetomidine is a Alpha-2 adrenergic agonist Small molecule drug developed by Nanjing First Hospital, Nanjing Medical University. It is currently FDA-approved for Intraoperative sedation and analgesia during surgical procedures, Perioperative anxiolysis.

Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating alpha-2 receptors in the central nervous system.

Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating alpha-2 receptors in the central nervous system. Used for Intraoperative sedation and analgesia during surgical procedures, Perioperative anxiolysis.

At a glance

Generic nameIntraoperative infusion of dexmedetomidine
SponsorNanjing First Hospital, Nanjing Medical University
Drug classAlpha-2 adrenergic agonist
TargetAlpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaAnesthesia/Perioperative Medicine
PhaseFDA-approved

Mechanism of action

Dexmedetomidine binds to alpha-2 adrenergic receptors in the locus coeruleus and other brain regions, reducing norepinephrine release and producing a unique sedative state characterized by maintained airway reflexes and responsiveness to stimulation. When used as an intraoperative infusion, it provides sedation and analgesia while preserving respiratory drive, making it useful for perioperative anxiolysis and analgesia reduction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intraoperative infusion of dexmedetomidine

What is Intraoperative infusion of dexmedetomidine?

Intraoperative infusion of dexmedetomidine is a Alpha-2 adrenergic agonist drug developed by Nanjing First Hospital, Nanjing Medical University, indicated for Intraoperative sedation and analgesia during surgical procedures, Perioperative anxiolysis.

How does Intraoperative infusion of dexmedetomidine work?

Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating alpha-2 receptors in the central nervous system.

What is Intraoperative infusion of dexmedetomidine used for?

Intraoperative infusion of dexmedetomidine is indicated for Intraoperative sedation and analgesia during surgical procedures, Perioperative anxiolysis.

Who makes Intraoperative infusion of dexmedetomidine?

Intraoperative infusion of dexmedetomidine is developed and marketed by Nanjing First Hospital, Nanjing Medical University (see full Nanjing First Hospital, Nanjing Medical University pipeline at /company/nanjing-first-hospital-nanjing-medical-university).

What drug class is Intraoperative infusion of dexmedetomidine in?

Intraoperative infusion of dexmedetomidine belongs to the Alpha-2 adrenergic agonist class. See all Alpha-2 adrenergic agonist drugs at /class/alpha-2-adrenergic-agonist.

What development phase is Intraoperative infusion of dexmedetomidine in?

Intraoperative infusion of dexmedetomidine is FDA-approved (marketed).

What are the side effects of Intraoperative infusion of dexmedetomidine?

Common side effects of Intraoperative infusion of dexmedetomidine include Hypotension, Bradycardia, Hypertension (transient, initial), Dry mouth, Dizziness.

What does Intraoperative infusion of dexmedetomidine target?

Intraoperative infusion of dexmedetomidine targets Alpha-2 adrenergic receptor and is a Alpha-2 adrenergic agonist.

Related